. "This is in contrast to 2004's global economic and political climates, which saw the company having to ride out tough economic conditions while continuing to invest in opportunities for creating future value.2006 has seen six new programmes in-licensed during the year, including a series of selective EP4 receptor antagonists designed to treat conditions such as migraine headaches.Its lead compound," . . .